Heart failure has historically been irreversible, but the outcome of a new study suggests that could someday change. At the University of Utah, scientists used a new gene therapy that was shown to reverse the effects of heart failure in a large animal study. In the study, pigs with heart failure were found to have low levels of cardiac bridging integrator 1 (cBIN1), a critical heart protein. The scientists injected a harmless virus into the pigs’ bloodstreams to carry the cBIN1 gene into their heart cells, according to a university press release. The pigs survived for the six-month duration of the study, while they would have been expected to die from heart failure without the gene therapy. In what the researchers called an “unprecedented recovery of cardiac function,” the IV injection appeared to improve heart function by increasing the amount of blood it can pump, which “dramatically improves survival.” The pigs’ hearts also appeared to be “less dilated and less thinned out” after the therapy, “closer in appearance to that of non-failing hearts.” “Even though the animals are still facing stress on the heart to induce heart failure, in animals that got the treatment, we saw recovery of heart function and that the heart also stabilizes or shrinks,” said TingTing Hong, MD, PhD, associate professor of pharmacology and toxicology at the University of Utah, in the release. “We call this reverse remodeling. It’s going back to what the normal heart should look like.” “A possible new therapy to cure heart failure is on the way,” Hong told Fox News Digital in a statement. The researchers were surprised to find that the gene therapy worked so well in large animals at such a low dose, Hong added. Co-senior author Robin Shaw, MD, PhD, director of the Nora Eccles Harrison Cardiovascular Research and Training Institute at the University of Utah, said the “unprecedented” study ushers in a “new paradigm” for heart failure treatments. “Given our treatment efficacy, the complex multi-organ syndrome of heart failure can be reduced to a treatable disease of failing heart muscle,” he told Fox News Digital via email. “The toxicity of gene therapy increases with dose, so our low dose suggests that our gene therapy approach will be safe for patients. While gene therapy has historically been used for rare diseases, the study results suggest that it could also be an effective approach for “acquired disease,” according to Shaw. The study did have some limitations, the researchers acknowledged. “Dose escalation and toxicology studies are still needed for the therapy to move to the next step [toward FDA approval],” Hong noted.  It is also uncertain whether the gene therapy will work for people who have obtained a natural immunity to the virus that carries the therapy, the researchers said. The toxicology study is currently underway, and the team plans to start human clinical trials in the fall of 2025, Hong said. Cardiologists weigh in Dr. Jasdeep Dalawari, interventional cardiologist and regional chief medical officer at VitalSolution, an Ingenovis Health Company based in Ohio, was not involved in the research but shared his reaction to the findings. “Gene therapy, precision medicine and personalized health care is the future.” “Research in the animal phase is always interesting, but the application to human test subjects is necessary in terms of understanding if this approach would have the same effect in humans,” he told Fox News Digital. “That said, there are many genetic modifications happening in different diseases, like cystic fibrosis and muscular dystrophy, that are looking at a similar intervention – injecting healthy genes in the hopes of finding cures,” he went on. “Gene therapy, precision medicine and personalized health care is the future, and I look forward to learning more about this.” Dr. Johanna Contreras, advanced heart failure and transplant cardiologist at the Mount Sinai Fuster Heart Hospital in New York City, noted that conventional pharmacological interventions can help to alleviate cardiac stress and “systemic congestion,” but “for the most part, they do not address the pathogenic remodeling of failing heart muscle.”